Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

by · The Markets Daily

Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) has earned an average rating of “Moderate Buy” from the seventeen brokerages that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $30.35.

NRIX has been the subject of a number of research analyst reports. Oppenheimer lifted their target price on shares of Nurix Therapeutics from $27.00 to $30.00 and gave the company an “outperform” rating in a research note on Wednesday, September 4th. UBS Group initiated coverage on Nurix Therapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $35.00 target price on the stock. Jefferies Financial Group began coverage on shares of Nurix Therapeutics in a research report on Friday, October 11th. They set a “buy” rating and a $41.00 price target on the stock. Robert W. Baird started coverage on shares of Nurix Therapeutics in a research report on Friday, September 6th. They issued an “outperform” rating and a $26.00 price objective for the company. Finally, BTIG Research initiated coverage on shares of Nurix Therapeutics in a research report on Tuesday, December 10th. They set a “buy” rating and a $35.00 target price on the stock.

View Our Latest Analysis on NRIX

Nurix Therapeutics Price Performance

Shares of NASDAQ:NRIX opened at $19.98 on Tuesday. The business’s fifty day moving average price is $23.46 and its two-hundred day moving average price is $22.37. Nurix Therapeutics has a fifty-two week low of $7.65 and a fifty-two week high of $29.56. The stock has a market capitalization of $1.42 billion, a price-to-earnings ratio of -6.87 and a beta of 2.11.

Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) last posted its earnings results on Friday, October 11th. The company reported ($0.67) earnings per share for the quarter, hitting the consensus estimate of ($0.67). Nurix Therapeutics had a negative net margin of 313.65% and a negative return on equity of 63.39%. The business had revenue of $12.59 million for the quarter, compared to analyst estimates of $13.85 million. Research analysts expect that Nurix Therapeutics will post -2.81 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Gwenn Hansen sold 3,437 shares of the stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $24.30, for a total transaction of $83,519.10. Following the completion of the transaction, the insider now directly owns 50,670 shares of the company’s stock, valued at approximately $1,231,281. This represents a 6.35 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Houte Hans Van sold 3,546 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $24.28, for a total value of $86,096.88. Following the completion of the transaction, the chief financial officer now owns 33,724 shares of the company’s stock, valued at approximately $818,818.72. This represents a 9.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 18,401 shares of company stock valued at $437,453. 7.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Nurix Therapeutics

Several large investors have recently made changes to their positions in NRIX. Amalgamated Bank increased its holdings in Nurix Therapeutics by 30.6% during the third quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock worth $49,000 after buying an additional 511 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Nurix Therapeutics by 31.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company’s stock valued at $54,000 after acquiring an additional 559 shares during the period. Quarry LP increased its stake in shares of Nurix Therapeutics by 3,746.2% during the 3rd quarter. Quarry LP now owns 2,500 shares of the company’s stock worth $56,000 after purchasing an additional 2,435 shares during the last quarter. International Assets Investment Management LLC raised its holdings in shares of Nurix Therapeutics by 1,098.4% in the 3rd quarter. International Assets Investment Management LLC now owns 4,494 shares of the company’s stock valued at $101,000 after purchasing an additional 4,119 shares during the period. Finally, Quest Partners LLC grew its holdings in Nurix Therapeutics by 21.3% during the third quarter. Quest Partners LLC now owns 7,458 shares of the company’s stock worth $168,000 after purchasing an additional 1,312 shares during the period.

Nurix Therapeutics Company Profile

(Get Free Report

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

Recommended Stories